David Erb
Pulmonary Disease · Spartanburg, SCNPI 1952366478
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $9,683 of the $12,074 with a category attached, or 80.2%. It is spread thinly across 36 manufacturers, the largest accounting for just 11.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $3,398 and has fallen 93.4% since, to $224 in 2025.
Across 593 payments — averaging $20.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim International GmbH$1K
- Genentech USA, Inc.$1K
- AstraZeneca$1K
- Boehringer Ingelheim$1K
- GSK$1K
- Electromed, Inc.$819
- plus $5K from 30 others
Across 3,359 payments — averaging $2252.12 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Modernatx, Inc.$2.7M
- AstraZeneca$906K
- Seqirus USA Inc$888K
- Boehringer Ingelheim$699K
- Eli Lilly$495K
- Johnson & Johnson$299K
- plus $1.6M from 16 others
What the payments were for
- Travel & lodging$2,35820%
- Food & beverage$9,68380%
- Education$330%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim International GmbH | 11 | $1,439 |
| Genentech USA, Inc. | 15 | $1,343 |
| AstraZeneca | 50 | $1,211 |
| Boehringer Ingelheim | 66 | $1,190 |
| GSK | 78 | $1,041 |
| Electromed, Inc. | 70 | $819 |
| Actelion Pharmaceuticals US, Inc. | 23 | $526 |
| Gilead | 25 | $488 |
| Grifols USA, LLC | 34 | $481 |
| Philips North America LLC | 23 | $426 |
| Sunovion Pharmaceuticals Inc. | 29 | $399 |
| Sanofi | 20 | $335 |
| Insmed, Inc. | 25 | $314 |
| Mylan Specialty L.p. | 15 | $270 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $235 |
| Regeneron Healthcare Solutions, Inc. | 11 | $234 |
| Johnson & Johnson | 16 | $194 |
| Amgen | 9 | $157 |
| United Therapeutics Corporation | 7 | $142 |
| Novartis | 8 | $139 |
| Teva Pharmaceuticals USA, Inc. | 8 | $109 |
| Advanced Respiratory, Inc | 4 | $78 |
| Resmed Corp | 5 | $77 |
| ANI Pharmaceuticals, Inc. | 5 | $67 |
| Circassia Inc. | 4 | $61 |
| Jazz Pharmaceuticals Inc. | 2 | $43 |
| Bayer | 3 | $43 |
| Inogen, Inc. | 3 | $41 |
| Mallinckrodt Hospital Products Inc. | 2 | $38 |
| Pulmonx Corporation | 2 | $33 |
| Merck | 2 | $29 |
| Body Vision Medical Inc. | 1 | $23 |
| Tetraphase Pharmaceuticals, Inc. | 1 | $15 |
| Vapotherm Inc | 1 | $13 |
| Shire North American Group Inc | 1 | $12 |
| Nabriva Therapeutics, PLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,074 in reported general payments places this provider in the 80th percentile of 192 pulmonary disease providers in South Carolina.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 12 | $11,142 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 23 | $1,077 |
| Amlodipine Besylate | 18 | $122 |
| Furosemide | 15 | $5 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta | $1,041 | $11,14212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 192 pulmonary disease providers in South Carolina.
Other pulmonary disease in Spartanburg
- Joseph BosciaSpartanburg$701K
- Farhan SiddiquiSpartanburg$24K
- Charles FogartySpartanburg$10K
- Abhijit RavalAnderson$2M
- Richard BoganColumbia$1.1M
- Patrick FlumeCharleston$418K
- Sean CallahanGreenville$321K
- Laura HerpelColumbia$254K
- Gerard SilvestriCharleston$254K
- Arun AdlakhaRock Hill$184K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.